Retinal Disease & Cataract Surgery | Dr. Sun Xiaodong (Ophthalmology) | CMCS Shanghai

About Dr. Sun Xiaodong

Dr. Sun Xiaodong is Chief of Ophthalmology at Shanghai General Hospital, Shanghai Jiao Tong University — one of China's leading centres for retinal vascular disease and complex cataract surgery. He specialises in diabetic retinopathy, age-related macular degeneration, and refractive cataract surgery, and is a leading researcher in retinal pharmacotherapy and intraocular lens optics. Dr. Sun has published extensively in international ophthalmology journals including Ophthalmology and regularly treats international patients seeking advanced retinal and cataract care that is unavailable or unaffordable in their home countries. His practice integrates surgical precision with evidence-based pharmacological management to deliver comprehensive, whole-journey ophthalmic care.

Case Overview

Mr. David Anderson, a 62-year-old American senior partner at a multinational consulting firm, presented with 1 year of progressive right eye visual decline and 1 week of sudden visual loss from vitreous haemorrhage. His right eye was his only functional eye — the left having been rendered near-blind by prior retinal detachment surgery. Fifteen years of poorly controlled type 2 diabetes (HbA1c 8.5–9.0%) had produced proliferative diabetic retinopathy with active vitreous haemorrhage, macular oedema, and a Grade IV dense nuclear cataract. His professional demands — high-frequency reading, driving, and screen use — required not merely restored vision but high-quality, spectacle-independent vision across all distances. Dr. Sun Xiaodong performed a single-session triple procedure: femtosecond laser-assisted phacoemulsification with EDOF toric IOL implantation, 23-gauge pars plana vitrectomy with proliferative membrane peeling and pan-retinal photocoagulation, and intravitreal ranibizumab injection. Operative time 95 minutes. On post-operative day 1, the patient achieved 0.8 distance and 0.6 near vision without spectacles. At 3-month follow-up, distance vision was 1.0 and near vision 0.8; macular oedema had resolved; no neovascular glaucoma had developed. The patient had resumed full professional activity including night driving without glare.

Patient Background

• Name / Nationality: Mr. David Anderson (pseudonym) — American
• Age / Sex: 62-year-old male
• Occupation: Senior partner, multinational consulting firm — high-frequency reading, driving, and digital device use are professional necessities
• Chief Complaint: Progressive right eye visual decline for 1 year; sudden visual loss from vitreous haemorrhage for 1 week
• Systemic History: Type 2 diabetes mellitus for 15 years — HbA1c 8.5–9.0% (poorly controlled); hypertension
• Ocular History: Bilateral high myopia (-8.0 D); left eye: prior retinal detachment surgery with residual vision of light perception only; right eye: sole functional eye

Pre-operative Assessment and Diagnosis

Ocular Examination

• Right eye visual acuity: Counting fingers at 30 cm (combined cataract and vitreous haemorrhage)
• Lens: Nuclear hardness Grade C4N3 — extremely dense nuclear cataract with posterior subcapsular opacity; high phacoemulsification energy requirement anticipated
• Fundus: Direct visualisation impossible due to vitreous haemorrhage; B-scan ultrasound demonstrated retinal traction and early detachment tendency with macular involvement

Imaging

• OCT: Right eye — macular hard exudates and cystoid macular oedema (DME) visible through haemorrhage; left eye — macular atrophy
• IOL Master 700 biometry: Axial length 28.5 mm (high myopia); corneal endothelial cell count 2,200 cells/mm² — borderline reserve requiring energy minimisation strategy
• FFA (left eye reference): Extensive retinal non-perfusion zones and active neovascularisation — confirming proliferative diabetic retinopathy pattern applicable to the right eye

Diagnosis

• Right eye: Grade IV nuclear cataract; proliferative diabetic retinopathy; vitreous haemorrhage; diabetic macular oedema
• Left eye: Post-retinal detachment repair; sensory exotropia; complicated cataract; light perception only

Clinical Decision Making and Surgical Planning

Conventional management of active proliferative diabetic retinopathy combined with cataract would stage the procedures: cataract surgery first, followed by vitreoretinal surgery once the fundus stabilised. For a patient with a single functional eye, this approach carried unacceptable risks: post-cataract inflammation accelerating diabetic retinopathy progression and triggering neovascular glaucoma; two separate surgical insults to the only seeing eye; and a single-focus IOL leaving the patient spectacle-dependent for near and intermediate vision despite the complexity of the surgery.

Dr. Sun Xiaodong's single-session integrated strategy: This patient has one eye. Every surgical intervention carries risk, and we cannot afford two procedures when one will suffice. More importantly, this is a professional who needs spectacle-independent vision across all distances — not simply light perception restored. I have decided on a triple procedure in a single session: femtosecond laser-assisted phacoemulsification to minimise ultrasound energy and protect the corneal endothelium; 23-gauge vitrectomy to clear the haemorrhage, peel the proliferative membranes, and laser the non-perfusion zones; and intravitreal ranibizumab to suppress VEGF, prevent neovascular glaucoma, and accelerate macular oedema resolution. The IOL will be a Tecnis Symfony Toric EDOF lens — calculated with the Barrett Universal II formula targeting mild myopia of -0.5 D, correcting his astigmatism and providing spectacle-free vision from distance through near.

Surgical Procedure

Approach: Femtosecond laser-assisted phacoemulsification + EDOF toric IOL implantation + 23-gauge pars plana vitrectomy + pan-retinal photocoagulation + intravitreal ranibizumab
Anaesthesia: Topical anaesthesia + peribulbar block (with sedation)
Operative time: 95 minutes

Step 1 — Femtosecond Laser Pre-treatment (LensX)

With the patient positioned under the femtosecond laser platform, automated corneal incisions (main and side-port), a perfectly centred anterior capsulotomy, and nuclear pre-fragmentation into six segments were completed. The pre-fragmentation reduced the phacoemulsification cumulative dissipated energy (CDE) to one-third of that required for conventional Grade IV nuclear removal — a critical protection measure for the borderline corneal endothelial cell count of 2,200 cells/mm².

Step 2 — Phacoemulsification and IOL Implantation

The pre-fragmented nuclear segments were aspirated with minimal ultrasound energy. A Tecnis Symfony Toric EDOF IOL was implanted and aligned to the correct astigmatic axis under intraoperative OCT guidance (Resight 700), ensuring precise toric orientation for maximum astigmatic correction.

Step 3 — Vitreoretinal Surgery (Critical Phase)

Three 23-gauge pars plana ports were established. Central vitrectomy was performed, revealing dense vitreous haemorrhage and inferior proliferative membranes exerting traction on the macula. The Constellation Vision System's high-speed vitreous cutter was used to remove proliferative membranes and relieve macular traction. Throughout this phase, meticulous care was taken to avoid contact with the newly implanted IOL and posterior capsule.

Step 4 — Retinal Laser and Pharmacological Treatment

Air-fluid exchange was performed to flatten the retina. Pan-retinal photocoagulation (PRP) was applied to all identified non-perfusion zones. Immediately prior to wound closure, intravitreal ranibizumab 0.5 mg was injected — suppressing the VEGF pathway to prevent post-operative neovascular glaucoma, accelerate macular oedema resolution, and reduce the inflammatory response in this high-risk diabetic eye.

Dr. Sun's operative note: The intravitreal anti-VEGF injection at the conclusion of combined surgery is not an afterthought — it is the pharmacological safety net for the entire procedure. In a diabetic eye with active proliferative disease, the surgical trauma of phacoemulsification and vitrectomy will trigger an inflammatory and angiogenic response. The ranibizumab intercepts that response before it begins. It is the difference between a smooth post-operative course and a neovascular glaucoma crisis in the patient's only eye.

Post-operative Management and Visual Outcomes

Post-operative Day 1

• Distance vision: 0.8 (unaided)
• Intermediate vision: 0.8 (unaided)
• Near vision: 0.6 (unaided)
• Intraocular pressure: 14 mmHg
• Cornea: Clear; no oedema
• Patient response: I can read my phone and documents without glasses. I did not expect this after everything that was wrong with my eye.

1-Week Follow-up

• OCT: Central macular thickness reduced from 450 μm to 280 μm — macular oedema substantially resolved
• Fundus: Retina flat; laser photocoagulation scars well-defined; no active haemorrhage

3-Month Follow-up

• Distance vision: 1.0 (unaided)
• Near vision: 0.8 (unaided)
• Contrast sensitivity: Normal
• Night driving: No glare or haloes reported
• Intraocular pressure: Normal; no neovascular glaucoma
• Professional status: Fully returned to work; driving, reading, and screen use without spectacles

Extended Case: Anti-VEGF Resistant Neovascular AMD

Dr. Sun Xiaodong's expertise extends beyond surgical management to the pharmacological frontier of retinal vascular disease.

A 75-year-old woman with neovascular age-related macular degeneration (nAMD) had received 12 intravitreal ranibizumab injections with persistent subretinal fluid and progressive visual decline — a pattern consistent with anti-VEGF resistance. Dr. Sun's management strategy: genetic testing identified a high-risk CFH gene variant associated with complement pathway dysregulation; treatment was switched to high-dose aflibercept on a treat-and-extend protocol; photodynamic therapy (PDT) was added to target the underlying polypoidal choroidal vasculopathy (PCV). At 3 months, subretinal fluid had completely resolved and visual acuity improved from 0.1 to 0.4. This case was published by Dr. Sun's team in Ophthalmology, contributing a pharmacogenomic framework for managing anti-VEGF resistant nAMD.

Expert Commentary — Dr. Sun Xiaodong

1. Refractive Cataract Surgery: Vision Reconstruction, Not Simply Vision Restoration

For a high myope with professional visual demands, restoring light perception is not the goal — spectacle-independent, high-quality vision across all distances is the goal. EDOF and multifocal IOLs, combined with toric correction and precise biometric calculation using the Barrett Universal II formula, make this achievable even in the context of complex combined surgery. The IOL calculation must account for the long axial length, the post-vitrectomy refractive shift, and the patient's specific occupational visual requirements. Precision biometry is not a pre-operative formality — it is the foundation of the refractive outcome.

2. Risk Management in Combined Phaco-Vitrectomy

The two principal risks of combined surgery in diabetic patients are corneal endothelial decompensation and posterior capsule rupture. Femtosecond laser pre-fragmentation reduces phacoemulsification energy by up to 70% in dense nuclei — directly protecting the endothelium. Viscoelastic agent use throughout the anterior segment phase provides additional endothelial protection. Intraoperative anti-VEGF injection at the conclusion of the procedure is the pharmacological equivalent of a surgical safety net: it suppresses the post-operative angiogenic and inflammatory cascade before it can cause neovascular glaucoma or macular oedema recurrence. These are not optional refinements. In a diabetic patient with a single functional eye, they are mandatory.

3. Evidence-Based Individualised Treatment

Whether selecting ranibizumab or aflibercept, single-focus or EDOF IOL, treat-and-extend or fixed-interval injection protocol — every decision must be grounded in the individual patient's genetic background, ocular anatomy, and life requirements. Pharmacogenomics is entering clinical ophthalmology: CFH and ARMS2 genotyping now informs anti-VEGF drug selection in refractory AMD. IOL optical design selection must account for the patient's pupil dynamics, corneal aberrations, and occupational lighting conditions. The ophthalmologist who applies a single protocol to every patient is not practising evidence-based medicine.

4. International Medical Standards in Shanghai

International patients require not only technical excellence but seamless, multilingual, whole-journey care. From pre-operative biometric assessment and multilingual surgical consent to post-operative remote monitoring and home-country physician communication, our centre has established a care pathway aligned with international standards. The technology we use — femtosecond laser platforms, intraoperative OCT, 23-gauge vitrectomy systems, EDOF IOL optics — is identical to that available at leading centres in the United States and Europe. The difference is access, waiting time, and cost. For international patients in Shanghai, we offer all three advantages simultaneously.

How CMCS Shanghai Coordinated This Case

China Medical Concierge Shanghai (CMCS) supported Mr. Anderson's care pathway from initial overseas inquiry through 3-month visual rehabilitation. Our coordination included:

• Pre-arrival review of ophthalmic records, prior retinal detachment surgical notes, and diabetic eye disease history; specialist referral to Dr. Sun Xiaodong's ophthalmology team at Shanghai General Hospital, Shanghai Jiao Tong University
• Arrangement of IOL Master 700 biometry, corneal endothelial cell count, OCT macular mapping, B-scan ultrasound, and fluorescein angiography for complete pre-operative assessment
• Bilingual interpretation during the surgical planning consultation, including detailed explanation of the triple procedure rationale, femtosecond laser technique, EDOF toric IOL optics, vitrectomy approach, and realistic visual outcome expectations for a single functional eye
• IOL selection consultation: discussion of EDOF versus multifocal options in the context of diabetic macular disease, occupational visual demands, and night driving requirements
• Surgical admission logistics: hospital registration, femtosecond laser and vitreoretinal suite scheduling, and accommodation support
• Post-operative monitoring coordination: day 1, week 1, and month 1 follow-up appointment scheduling with Dr. Sun's team; OCT and intraocular pressure surveillance; results translation and communication to Mr. Anderson's home ophthalmologist in the United States
• HbA1c optimisation liaison: coordination with the patient's endocrinologist for pre-operative glycaemic control improvement and post-operative diabetic management to protect the surgical outcome
• 3-month final assessment coordination: visual acuity, contrast sensitivity, and fundus surveillance reporting for the patient's home medical records

For international patients facing complex diabetic eye disease — particularly those with combined cataract and retinal pathology in a single functional eye, or those who have been told that spectacle-independent vision is not achievable in the context of retinal disease — the combination of femtosecond laser precision, advanced vitreoretinal surgical capability, and EDOF IOL expertise at Shanghai's leading ophthalmology centres represents a standard of care that is fully equivalent to the world's best. CMCS exists to connect patients with that expertise: ensuring every visual rehabilitation option is evaluated, every surgical risk is explained in their language, and every step from pre-operative biometry to long-term retinal surveillance is coordinated with precision and care.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.